Pancreatic cancer immunotherapy (Cell Genesys)

N/A

Report date: 2022/02/18 15:13:04

Base Information

Drug NamePancreatic cancer immunotherapy (Cell Genesys)
Drug Alias NameCG-8020 + CG-2505GM-CSF–secreting pancreatic cancer cell line-based immunotherapy (Cancer)
ClassificationCell and gene therapy > Cell therapy
Mechanisms of ActionMacrophage colony stimulating factor 2 stimulants
TargetsMacrophage colony stimulating factor 2
Therapy Area/IndicationsPancreatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBiosante Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBiosante Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsPancreatic Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A